ofatumumab

ofatumumab Struktur
679818-59-8
CAS-Nr.
679818-59-8
Englisch Name:
ofatumumab
Synonyma:
ofatumumab;Ofatumumab (anti-CD20);Research Grade Ofatumumab(DHC90701)
CBNumber:
CB91508605
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

ofatumumab Eigenschaften

Sicherheit

Giftige Stoffe Daten 679818-59-8(Hazardous Substances Data)

ofatumumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Considered as the most common form of leukemia in adults, CLL is characterized by the accumulation of abnormal B lymphocytes and manifests itself as lymph node enlargement and bone marrow failure in symptomatic patients. Ofatumumab is the second marketed mAb to target CD20. Compared to its predecessor,it is a fully human mAb that was generated via transgenic mouse and hybridoma technology. In addition to the Fab portion that recognizes CD20, the Fc domain mediates immune effector functions to lyse cells via complement-dependent cytotoxicity (CDC) and antibody-dependent, cell-mediated cytotoxicity (ADCC). Ofatumumab targets a different, discontinuous epitope on CD20 than rituximab; it binds specifically to both the small and large extracellular loops of the CD20 molecule expressed on normal B lymphocytes and on B-cell CL, and its binding does not induce receptor internalization nor shedding from the cell surface. In addition to targeting a different epitope on CD20, ofatumumab also exhibits a slower off-rate. These characteristics have been proposed as reasons for its ability to lyse rituximab-resistant cells that express low levels of CD20 and for its greater in vitro activity against CLL cells versus rituximab.
The most common adverse events were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.

Originator

Genmab (Denmark)

Trademarks

Arzerra

ofatumumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


ofatumumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 25)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
TargetMol Chemicals Inc.
+1-781-999-5354
support@targetmol.com United States 19973 58
Wuhan Topule Biopharmaceutical Co., Ltd
+8618327326525
masar@topule.com China 8474 58
Aladdin Scientific
+1-833-552-7181
sales@aladdinsci.com United States 57511 58
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2127 70
Dalian Meilun Biotech Co., Ltd. 0411-62910999 13889544652
sales@meilune.com China 4662 58
NCE Biomedical Co.,Ltd. 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
China 1494 55
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627
info@efebio.com China 9709 58
ShangHai Biochempartner Co.,Ltd 17754423994 17754423994
2853530910@QQ.com China 8011 62
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062
422450190@qq.com China 10055 58
Wuhan Topule +86-02787215551 +86-19945035818
2936752263@qq.com China 8287 58

679818-59-8()Verwandte Suche:


  • ofatumumab
  • Research Grade Ofatumumab(DHC90701)
  • Ofatumumab (anti-CD20)
  • 679818-59-8
Copyright 2019 © ChemicalBook. All rights reserved